{"pmid":32260155,"title":"Process-Induced Nanostructures on Anatase Single Crystals via Pulsed-Pressure MOCVD.","text":["Process-Induced Nanostructures on Anatase Single Crystals via Pulsed-Pressure MOCVD.","The recent global pandemic of COVID-19 highlights the urgent need for practical applications of anti-microbial coatings on touch-surfaces. Nanostructured TiO2 is a promising candidate for the passive reduction of transmission when applied to handles, push-plates and switches in hospitals. Here we report control of the nanostructure dimension of the mille-feuille crystal plates in anatase columnar crystals as a function of the coating thickness. This nanoplate thickness is key to achieving the large aspect ratio of surface area to migration path length. TiO2 solid coatings were prepared by pulsed-pressure metalorganic chemical vapor deposition (pp-MOCVD) under the same deposition temperature and mass flux, with thickness ranging from 1.3-16 mm, by varying the number of precursor pulses. SEM and STEM were used to measure the mille-feuille plate width which is believed to be a key functional nano-dimension for photocatalytic activity. Competitive growth produces a larger columnar crystal diameter with thickness. The question is if the nano-dimension also increases with columnar crystal size. We report that the nano-dimension increases with the film thickness, ranging from 17-42 nm. The results of this study can be used to design a coating which has co-optimized thickness for durability and nano-dimension for enhanced photocatalytic properties.","Materials (Basel)","Gorthy, Rukmini","Krumdieck, Susan","Bishop, Catherine","32260155"],"abstract":["The recent global pandemic of COVID-19 highlights the urgent need for practical applications of anti-microbial coatings on touch-surfaces. Nanostructured TiO2 is a promising candidate for the passive reduction of transmission when applied to handles, push-plates and switches in hospitals. Here we report control of the nanostructure dimension of the mille-feuille crystal plates in anatase columnar crystals as a function of the coating thickness. This nanoplate thickness is key to achieving the large aspect ratio of surface area to migration path length. TiO2 solid coatings were prepared by pulsed-pressure metalorganic chemical vapor deposition (pp-MOCVD) under the same deposition temperature and mass flux, with thickness ranging from 1.3-16 mm, by varying the number of precursor pulses. SEM and STEM were used to measure the mille-feuille plate width which is believed to be a key functional nano-dimension for photocatalytic activity. Competitive growth produces a larger columnar crystal diameter with thickness. The question is if the nano-dimension also increases with columnar crystal size. We report that the nano-dimension increases with the film thickness, ranging from 17-42 nm. The results of this study can be used to design a coating which has co-optimized thickness for durability and nano-dimension for enhanced photocatalytic properties."],"journal":"Materials (Basel)","authors":["Gorthy, Rukmini","Krumdieck, Susan","Bishop, Catherine"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32260155","week":"202015|Apr 06 - Apr 12","doi":"10.3390/ma13071668","keywords":["anatase single crystals","competitive growth","pp-MOCVD","process-induced nanostructures"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1663609715870924800,"score":7.9164424,"similar":[{"pmid":32236856,"title":"Ultra-high-resolution computed tomography can demonstrate alveolar collapse in novel coronavirus (COVID-19) pneumonia.","text":["Ultra-high-resolution computed tomography can demonstrate alveolar collapse in novel coronavirus (COVID-19) pneumonia.","PURPOSE: To review the chest computed tomography (CT) findings on the ultra-high-resolution CT (U-HRCT) in patients with the Novel coronavirus disease 2019 (COVID-19). MATERIALS AND METHODS: In February 2020, six consecutive patients with COVID-19 pneumonia (median age, 69 years) underwent U-HR CT imaging. U-HR-CT has a larger matrix size of 1024 x 1024 thinner slice thickness of 0.25 mm and can demonstrate terminal bronchioles in the normal lungs; as a result, Reid's secondary lobules and their abnormalities can be identified. The distribution and hallmarks (ground-glass opacity, consolidation with or without architectural distortion, linear opacity, crazy paving) of the lung opacities on U-HRCT were visually evaluated on a 1 K monitor by two experienced reviewers. The CT lung volume was measured, and the ratio of the measured lung volume to the predicted total lung capacity (predTLC) based on sex, age and height was calculated. RESULTS: All cases showed crazy paving pattern in U-HRCT. In these lesions, the secondary lobules were smaller than those in the un-affected lungs. CT lung volume decreased in two cases comparing predTLC. CONCLUSION: U-HRCT can evaluate not only the distribution and hallmarks of COVID-19 pneumonia but also visualize local lung volume loss.","Jpn J Radiol","Iwasawa, Tae","Sato, Midori","Yamaya, Takafumi","Sato, Yozo","Uchida, Yoshinori","Kitamura, Hideya","Hagiwara, Eri","Komatsu, Shigeru","Utsunomiya, Daisuke","Ogura, Takashi","32236856"],"abstract":["PURPOSE: To review the chest computed tomography (CT) findings on the ultra-high-resolution CT (U-HRCT) in patients with the Novel coronavirus disease 2019 (COVID-19). MATERIALS AND METHODS: In February 2020, six consecutive patients with COVID-19 pneumonia (median age, 69 years) underwent U-HR CT imaging. U-HR-CT has a larger matrix size of 1024 x 1024 thinner slice thickness of 0.25 mm and can demonstrate terminal bronchioles in the normal lungs; as a result, Reid's secondary lobules and their abnormalities can be identified. The distribution and hallmarks (ground-glass opacity, consolidation with or without architectural distortion, linear opacity, crazy paving) of the lung opacities on U-HRCT were visually evaluated on a 1 K monitor by two experienced reviewers. The CT lung volume was measured, and the ratio of the measured lung volume to the predicted total lung capacity (predTLC) based on sex, age and height was calculated. RESULTS: All cases showed crazy paving pattern in U-HRCT. In these lesions, the secondary lobules were smaller than those in the un-affected lungs. CT lung volume decreased in two cases comparing predTLC. CONCLUSION: U-HRCT can evaluate not only the distribution and hallmarks of COVID-19 pneumonia but also visualize local lung volume loss."],"journal":"Jpn J Radiol","authors":["Iwasawa, Tae","Sato, Midori","Yamaya, Takafumi","Sato, Yozo","Uchida, Yoshinori","Kitamura, Hideya","Hagiwara, Eri","Komatsu, Shigeru","Utsunomiya, Daisuke","Ogura, Takashi"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32236856","week":"202014|Mar 30 - Apr 05","doi":"10.1007/s11604-020-00956-y","keywords":["Crazy-paving pattern","Novel coronavirus","Pneumonia","Ultra-high-resolution computed tomography"],"source":"PubMed","locations":["U-HRCT"],"topics":["Diagnosis"],"weight":1,"_version_":1663352135526383616,"score":112.87304},{"pmid":32225175,"title":"Structural basis of receptor recognition by SARS-CoV-2.","text":["Structural basis of receptor recognition by SARS-CoV-2.","A novel SARS-like coronavirus (SARS-CoV-2) recently emerged and is rapidly spreading in humans(1,2). A key to tackling this epidemic is to understand the virus's receptor recognition mechanism, which regulates its infectivity, pathogenesis and host range. SARS-CoV-2 and SARS-CoV recognize the same receptor - human ACE2 (hACE2)(3,4). Here we determined the crystal structure of the SARS-CoV-2 receptor-binding domain (RBD) (engineered to facilitate crystallization) in complex with hACE2. Compared with the SARS-CoV RBD, a hACE2-binding ridge in SARS-CoV-2 RBD takes a more compact conformation; moreover, several residue changes in SARS-CoV-2 RBD stabilize two virus-binding hotspots at the RBD/hACE2 interface. These structural features of SARS-CoV-2 RBD enhance its hACE2-binding affinity. Additionally, we show that RaTG13, a bat coronavirus closely related to SARS-CoV-2, also uses hACE2 as its receptor. The differences among SARS-CoV-2, SARS-CoV and RaTG13 in hACE2 recognition shed light on potential animal-to-human transmission of SARS-CoV-2. This study provides guidance for intervention strategies targeting receptor recognition by SARS-CoV-2.","Nature","Shang, Jian","Ye, Gang","Shi, Ke","Wan, Yushun","Luo, Chuming","Aihara, Hideki","Geng, Qibin","Auerbach, Ashley","Li, Fang","32225175"],"abstract":["A novel SARS-like coronavirus (SARS-CoV-2) recently emerged and is rapidly spreading in humans(1,2). A key to tackling this epidemic is to understand the virus's receptor recognition mechanism, which regulates its infectivity, pathogenesis and host range. SARS-CoV-2 and SARS-CoV recognize the same receptor - human ACE2 (hACE2)(3,4). Here we determined the crystal structure of the SARS-CoV-2 receptor-binding domain (RBD) (engineered to facilitate crystallization) in complex with hACE2. Compared with the SARS-CoV RBD, a hACE2-binding ridge in SARS-CoV-2 RBD takes a more compact conformation; moreover, several residue changes in SARS-CoV-2 RBD stabilize two virus-binding hotspots at the RBD/hACE2 interface. These structural features of SARS-CoV-2 RBD enhance its hACE2-binding affinity. Additionally, we show that RaTG13, a bat coronavirus closely related to SARS-CoV-2, also uses hACE2 as its receptor. The differences among SARS-CoV-2, SARS-CoV and RaTG13 in hACE2 recognition shed light on potential animal-to-human transmission of SARS-CoV-2. This study provides guidance for intervention strategies targeting receptor recognition by SARS-CoV-2."],"journal":"Nature","authors":["Shang, Jian","Ye, Gang","Shi, Ke","Wan, Yushun","Luo, Chuming","Aihara, Hideki","Geng, Qibin","Auerbach, Ashley","Li, Fang"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32225175","week":"202014|Mar 30 - Apr 05","doi":"10.1038/s41586-020-2179-y","source":"PubMed","locations":["humans(1,2"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352135284162560,"score":94.44001},{"pmid":32181901,"title":"A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).","text":["A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).","During an outbreak of respiratory diseases including atypical pneumonia in Wuhan, a previously unknown beta-coronavirus was detected in patients. The newly discovered coronavirus is similar to some beta-coronaviruses found in bats but different from previously known SARS-CoV and MERS-CoV. High sequence identities and similarities between 2019-nCoV and SARS-CoV were found. In this study, we searched the homologous templates of all nonstructural and structural proteins of 2019-nCoV. Among the nonstructural proteins, the leader protein (nsp1), the papain-like protease (nsp3), the nsp4, the 3C-like protease (nsp5), the nsp7, the nsp8, the nsp9, the nsp10, the RNA-directed RNA polymerase (nsp12), the helicase (nsp13), the guanine-N7 methyltransferase (nsp14), the uridylate-specific endoribonuclease (nsp15), the 2'-O-methyltransferase (nsp16), and the ORF7a protein could be built on the basis of homology templates. Among the structural proteins, the spike protein (S-protein), the envelope protein (E-protein), and the nucleocapsid protein (N-protein) can be constructed based on the crystal structures of the proteins from SARS-CoV. It is known that PL-Pro, 3CL-Pro, and RdRp are important targets for design antiviral drugs against 2019-nCoV. And S protein is a critical target candidate for inhibitor screening or vaccine design against 2019-nCoV because coronavirus replication is initiated by the binding of S protein to cell surface receptors. It is believed that these proteins should be useful for further structure-based virtual screening and related computer-aided drug development and vaccine design.","J Med Virol","Dong, Shengjie","Sun, Jiachen","Mao, Zhuo","Wang, Lu","Lu, Yi-Lin","Li, Jiesen","32181901"],"abstract":["During an outbreak of respiratory diseases including atypical pneumonia in Wuhan, a previously unknown beta-coronavirus was detected in patients. The newly discovered coronavirus is similar to some beta-coronaviruses found in bats but different from previously known SARS-CoV and MERS-CoV. High sequence identities and similarities between 2019-nCoV and SARS-CoV were found. In this study, we searched the homologous templates of all nonstructural and structural proteins of 2019-nCoV. Among the nonstructural proteins, the leader protein (nsp1), the papain-like protease (nsp3), the nsp4, the 3C-like protease (nsp5), the nsp7, the nsp8, the nsp9, the nsp10, the RNA-directed RNA polymerase (nsp12), the helicase (nsp13), the guanine-N7 methyltransferase (nsp14), the uridylate-specific endoribonuclease (nsp15), the 2'-O-methyltransferase (nsp16), and the ORF7a protein could be built on the basis of homology templates. Among the structural proteins, the spike protein (S-protein), the envelope protein (E-protein), and the nucleocapsid protein (N-protein) can be constructed based on the crystal structures of the proteins from SARS-CoV. It is known that PL-Pro, 3CL-Pro, and RdRp are important targets for design antiviral drugs against 2019-nCoV. And S protein is a critical target candidate for inhibitor screening or vaccine design against 2019-nCoV because coronavirus replication is initiated by the binding of S protein to cell surface receptors. It is believed that these proteins should be useful for further structure-based virtual screening and related computer-aided drug development and vaccine design."],"journal":"J Med Virol","authors":["Dong, Shengjie","Sun, Jiachen","Mao, Zhuo","Wang, Lu","Lu, Yi-Lin","Li, Jiesen"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32181901","week":"202012|Mar 16 - Mar 22","doi":"10.1002/jmv.25768","keywords":["2019-nCoV","BLAST algorithm","CLUSTAL analysis","MERS-CoV","SARS-CoV","coronavirus","homology modeling","sequence alignment"],"source":"PubMed","locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352133837127680,"score":90.00833},{"pmid":32272481,"title":"Structure of M(pro) from COVID-19 virus and discovery of its inhibitors.","text":["Structure of M(pro) from COVID-19 virus and discovery of its inhibitors.","A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan(1-4). Currently there are no targeted therapeutics and effective treatment options remain very limited. In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (M(pro)). M(pro) is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus(5,6). Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus M(pro) in complex with this compound. Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of M(pro). Six of these compounds inhibited M(pro) with IC50 values ranging from 0.67 to 21.4 muM. Ebselen also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available.","Nature","Jin, Zhenming","Du, Xiaoyu","Xu, Yechun","Deng, Yongqiang","Liu, Meiqin","Zhao, Yao","Zhang, Bing","Li, Xiaofeng","Zhang, Leike","Peng, Chao","Duan, Yinkai","Yu, Jing","Wang, Lin","Yang, Kailin","Liu, Fengjiang","Jiang, Rendi","Yang, Xinglou","You, Tian","Liu, Xiaoce","Yang, Xiuna","Bai, Fang","Liu, Hong","Liu, Xiang","Guddat, Luke W","Xu, Wenqing","Xiao, Gengfu","Qin, Chengfeng","Shi, Zhengli","Jiang, Hualiang","Rao, Zihe","Yang, Haitao","32272481"],"abstract":["A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan(1-4). Currently there are no targeted therapeutics and effective treatment options remain very limited. In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (M(pro)). M(pro) is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus(5,6). Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus M(pro) in complex with this compound. Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of M(pro). Six of these compounds inhibited M(pro) with IC50 values ranging from 0.67 to 21.4 muM. Ebselen also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available."],"journal":"Nature","authors":["Jin, Zhenming","Du, Xiaoyu","Xu, Yechun","Deng, Yongqiang","Liu, Meiqin","Zhao, Yao","Zhang, Bing","Li, Xiaofeng","Zhang, Leike","Peng, Chao","Duan, Yinkai","Yu, Jing","Wang, Lin","Yang, Kailin","Liu, Fengjiang","Jiang, Rendi","Yang, Xinglou","You, Tian","Liu, Xiaoce","Yang, Xiuna","Bai, Fang","Liu, Hong","Liu, Xiang","Guddat, Luke W","Xu, Wenqing","Xiao, Gengfu","Qin, Chengfeng","Shi, Zhengli","Jiang, Hualiang","Rao, Zihe","Yang, Haitao"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32272481","week":"202015|Apr 06 - Apr 12","doi":"10.1038/s41586-020-2223-y","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663620083139739649,"score":88.65048},{"pmid":32243677,"title":"The COVID-19 outbreak in Italy: initial implications for organ transplantation programs.","text":["The COVID-19 outbreak in Italy: initial implications for organ transplantation programs.","The spread of Coronavirus Disease 2019 (COVID-19) has already reached a pandemic dimension within few weeks. Italy has been one of the first countries dealing with the outbreak of COVID-19 and severe measures have been adopted to limit viral transmission. The spread of COVID-19 may have several implications in organ transplant activity that physicians should be aware of. The initial experience gained during the COVID-19 outbreak shows that around 10% of infected patients in Italy need intensive care management to overcome the acute respiratory distress syndrome. Due to the exponential rise of infected patients we are now facing an actual risk of saturation of intensive care unit (ICU) beds. A restriction in the number of ICU beds available for both donors and transplant recipients may unfavorably influence the overall donation activity, and eventually lead to a reduced number of transplants. Preliminary Italian data show that a 25% reduction of procured organs has already occurred during the first 4 weeks of COVID-19 outbreak. This underlines the need to closely monitor what will be further happening in ICUs due to the COVID-19 spread in the attempt to preserve transplant activity, especially in Western countries where deceased donors represent the major organ resource.","Am J Transplant","Angelico, R","Trapani, S","Manzia, T M","Lombardini, L","Tisone, G","Cardillo, M","32243677"],"abstract":["The spread of Coronavirus Disease 2019 (COVID-19) has already reached a pandemic dimension within few weeks. Italy has been one of the first countries dealing with the outbreak of COVID-19 and severe measures have been adopted to limit viral transmission. The spread of COVID-19 may have several implications in organ transplant activity that physicians should be aware of. The initial experience gained during the COVID-19 outbreak shows that around 10% of infected patients in Italy need intensive care management to overcome the acute respiratory distress syndrome. Due to the exponential rise of infected patients we are now facing an actual risk of saturation of intensive care unit (ICU) beds. A restriction in the number of ICU beds available for both donors and transplant recipients may unfavorably influence the overall donation activity, and eventually lead to a reduced number of transplants. Preliminary Italian data show that a 25% reduction of procured organs has already occurred during the first 4 weeks of COVID-19 outbreak. This underlines the need to closely monitor what will be further happening in ICUs due to the COVID-19 spread in the attempt to preserve transplant activity, especially in Western countries where deceased donors represent the major organ resource."],"journal":"Am J Transplant","authors":["Angelico, R","Trapani, S","Manzia, T M","Lombardini, L","Tisone, G","Cardillo, M"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243677","week":"202014|Mar 30 - Apr 05","doi":"10.1111/ajt.15904","source":"PubMed","locations":["Italy","Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1663352135737147392,"score":85.62036}]}